Choose Your Country or Region

TAM receptors (Tyro-3,Axl,and Mertk)

Other Protein Tyrosine Kinase Related Inhibitors

VEGFR EGFR c-Met PDGFR CSF-1R IGF-1R c-Kit ALK Tie-2 HER2

Cat.No.	Product Name	Information	Product Use Citations	Product Validations
S9662	UNC2025	UNC2025 is a potent and orally active dual inhibitor of FLT3 and MER with IC50 of 0.35 nM and 0.46 nM, respectively. This compound also inhibits AXL, TRKA, TRKC, QIK, TYRO3, SLK, NuaK1, Kit (c-Kit) and Met (c-Met) with IC50 of 1.65 nM, 1.67 nM, 4.38 nM, 5.75 nM, 5.83 nM, 6.14 nM, 7.97 nM, 8.18 nM and 364 nM, respectively.	iScience, 2024, 27(7):110226 Commun Biol, 2023, 6(1):916 Int J Mol Sci, 2023, 10.3390/ijms242115903
S1119	Cabozantinib (XL184)	A potent VEGFR2 inhibitor with IC50 of 0.035 nM, Cabozantinib (XL184) also inhibits c-Met, Ret, Kit, Flt-1/3/4, Tie2, and AXL with IC50 of 1.3 nM, 4 nM, 4.6 nM, 12 nM/11.3 nM/6 nM, 14.3 nM and 7 nM in cell-free assays, respectively. It induces PUMA-dependent apoptosis in colon cancer cells via AKT/GSK-3β/NF-κB signaling pathway.	Nat Commun, 2025, 16(1):509 Cell Death Differ, 2025, 10.1038/s41418-025-01510-x Cell Death Dis, 2025, 16(1):76
S2841	Bemcentinib (R428)	Bemcentinib (R428, BGB324) is an inhibitor of Axl with IC50 of 14 nM, demonstrating >100-fold selectivity for Axl over Abl. This compound is also more than 50- to 100-fold selective for Axl versus Mer and Tyro3, and exhibits 100-fold greater selectivity compared to InsR, EGFR, HER2, and PDGFRβ.	Cell Stem Cell, 2025, S1934-5909(25)00265-6 J Clin Invest, 2025, e180893 Front Immunol, 2025, 16:1601420
S7067	Tepotinib	Tepotinib is a potent and selective c-Met inhibitor with IC50 of 4 nM, >200-fold selective for c-Met than IRAK4, TrkA, Axl, IRAK1, and Mer. This compound induces autophagy. Phase 1.	J Biomed Sci, 2025, 32(1):94 Cell Oncol (Dordr), 2025, 10.1007/s13402-025-01097-y Lung Cancer, 2025, 201:108415
S7754	ASP2215 (Gilteritinib)	Gilteritinib (ASP2215) is a small-molecule FLT3/AXL inhibitor with IC50 values of 0.29 nM and 0.73 nM for FLT3 and AXL, respectively. It inhibits FLT3 at an IC50 value that was approximately 800-fold more potent than the concentration required to inhibit c-KIT (230 nM).	J Adv Res, 2025, S2090-1232(25)00134-1 Cancer Lett, 2025, 611:217446 Mol Ther Nucleic Acids, 2025, 36(3):102611
E7462^New	Merestinib dihydrochloride	Merestinib dihydrochloride (LY2801653 dihydrochloride) is an orally bioavailable, potent c-Met inhibitor exhibiting a Ki value of 2 nM. This compound demonstrates antitumor activity and inhibits multiple kinases, including MST1R (IC50=11 nM), FLT3 (IC50=7 nM), AXL (IC50=2 nM), MERTK (IC50=10 nM), TEK (IC50=63 nM), ROS1, DDR1/2 (IC50=0.1/7 nM), and MKNK1/2 (IC50=7 nM).
S4001	Cabozantinib malate	Cabozantinib malate (XL184) is the malate of Cabozantinib, a potent VEGFR2 inhibitor with IC50 of 0.035 nM and also inhibits c-Met, Ret (c-Ret), Kit (c-Kit), Flt-1/3/4, Tie2, and AXL with IC50 of 1.3 nM, 4 nM, 4.6 nM, 12 nM/11.3 nM/6 nM, 14.3 nM and 7 nM in cell-free assays, respectively. This compound induces apoptosis.	Sci Rep, 2025, 15(1):35889 bioRxiv, 2025, 2025.08.15.670608 Nat Neurosci, 2024, 10.1038/s41593-024-01604-8
S1561	BMS-777607	BMS-777607 (BMS 817378) is a Met-related inhibitor for c-Met, Axl, Ron and Tyro3 with IC50 of 3.9 nM, 1.1 nM, 1.8 nM and 4.3 nM in cell-free assays, 40-fold more selective for Met-related targets versus Lck, VEGFR-2, and TrkA/B, and more than 500-fold greater selectivity versus all other receptor and non receptor kinases.	Cell Rep, 2025, 44(8):116096 Front Immunol, 2025, 16:1601420 Endocrinology, 2025, 166(11)bqaf146
S8696	2-D08	2-D08 (2',3',4'-trihydroxy flavone) is a cell permeable, mechanistically unique inhibitor of protein sumoylation. This compound is a cell permeable, mechanistically unique inhibitor of protein sumoylation.	Commun Biol, 2025, 8(1):1118 Int Immunopharmacol, 2025, 149:114187 Nat Commun, 2024, 15(1):9195
S7846	Dubermatinib(TP-0903)	Dubermatinib (TP-0903) is a potent and selective AXL Inhibitor with IC50 of 27 nM, and it is highly effective in inducing apoptosis.	Cancer Sci, 2025, 10.1111/cas.70151 Biol Direct, 2025, 20(1):77 Mol Oncol, 2024, 10.1002/1878-0261.13749
1 2

Signaling Pathway Map